12 July 2019 : Clinical Research
Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma
Yunhui Chan1BCDEF, Yipeng Yu2BCDF, Gang Wang2BCF, Changlin Wang2BCF, Daming Zhang34BCF, Xiaoxiong Wang4BF, Zichun Wang2BC, Wengang Jian2BC, Cheng Zhang2ADEDOI: 10.12659/MSM.915524
Med Sci Monit 2019; 25:5181-5190
Abstract
BACKGROUND: MicroRNA-381 (miR-381) is proven to be involved in many human tumors. Bioinformatics prediction suggests that miR-381 is decreased in renal cell carcinoma. However, its biological functions in clear-cell renal cell carcinoma (ccRCC) remain largely unknown. The present research aimed to evaluate miR-381 expression in renal cancer tissues and its effects on cell proliferation, growth, migration, and chemoresistance.
MATERIAL AND METHODS: Sixty pairs of ccRCC and the adjacent non-tumor specimens were collected during routine therapeutic surgery. Quantitative real-time PCR (qRT-PCR) assay was employed to examine miR-381 expression in the ccRCC tissues and the associated adjacent tissues (the normal tissues adjacent to tumor tissues). Cell transfection assay and Thiazolyl Blue Tetrazolium Bromide (MTT) assay were utilized to observe effects of miR-381 on the cell proliferation, growth, invasion, and chemoresistance in the Caki-1 cell line and 786-O cell line. Flow cytometry was used to assess cell apoptosis. Caki-1 cell and 786-O cell Xenograft BALB/c mouse models were established.
RESULTS: miR-381 expression was downregulated in ccRCC tissues in vivo and in cell lines in vitro. Downregulation of miR-381 promoted growth of cells and restrained the ccRCC cell apoptosis. Increased miR-381 combined with Ci and Pa suppressed the proliferation and enhanced the anti-tumor effects of Ci and Pa at tolerated concentrations in vitro. miR-381 inhibition promoted chemoresistance in vitro.
CONCLUSIONS: miR-381 levels were significantly downregulated in renal cancer tissues and miR-381 inhibition promoted tumor cell growth, migration, and chemoresistance.
Keywords: Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Drug Resistance, Aged, 80 and over, Cell Growth Processes, Down-Regulation, Kidney Neoplasms
Editorial
01 July 2026 : Editorial
Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development AcceleratesDOI: 10.12659/MSM.954627
Med Sci Monit 2026; 32:e954627
In Press
Review article
Clinical Use of Endotracheal Intubation Without Neuromuscular Blockade: The Current Stage of KnowledgeMed Sci Monit In Press; DOI: 10.12659/MSM.951765
Clinical Research
Effect of Dexmedetomidine Hydrochloride Nasal Spray on Anxiety and Sleep in Patients Undergoing Gynecologic...Med Sci Monit In Press; DOI: 10.12659/MSM.952465
Clinical Research
Prognostic Value of Mortality Scoring Systems in Patients With Severe Burns: Identifying Key Predictors of ...Med Sci Monit In Press; DOI: 10.12659/MSM.951713
Laboratory Research
Evaluation of the Trueness and Precision of Cast, Milled-Cast, Milled, and 3D-Printed Post-and-Core Techniq...Med Sci Monit In Press; DOI: 10.12659/MSM.953491
Most Viewed Current Articles
17 Jan 2024 : Review article 14,176,214
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,757,839
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,466,153
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 708,809
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






